In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Background The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to
cytoreductive surgery has been associated with encouraging survival results in some …

Peritoneal surface malignancies comprise a heterogeneous group of primary tumours,
including peritoneal mesothelioma, and peritoneal metastases of other tumours, including …

Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …

Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

Background This is the first updated Enhanced Recovery After Surgery (ERAS) Society
guideline presenting a consensus for optimal perioperative care in gynecologic/oncology …

Importance Ovarian cancer has the highest mortality rate among gynecologic malignant
tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal …